Evaluating a culturally adapted question prompt list to improve end-of-life communication among indonesian migrant caregivers: A randomized controlled trial with qualitative insights.

Patient Educ CounsJul 29, 2026 (epub)
Clinical ResearchPediatricsGeriatrics

Yu-Yun Den, Mei-Chuan Chang, Ying-Wei Wang

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated a culturally adapted Question Prompt List (QPL) aimed at improving end-of-life communication among 60 Indonesian caregivers in Taiwan. The intervention group reported significantly higher communication satisfaction and asked more questions compared to the control group, with p-values of <.05 and <.001, respectively.

Key findings

  • Communication satisfaction was significantly higher in the intervention group (F = 4.19, p < .05).
  • The number of questions asked was significantly higher in the intervention group (t = -4.35, p < .001).
  • No significant differences were found in caregiving preparedness or communication self-efficacy between groups.

Why it matters

Effective communication is crucial in end-of-life care, especially for caregivers facing cultural and language barriers. This study highlights the potential of culturally tailored tools to enhance caregiver engagement and satisfaction.

Source

PubMed · PMID 42542048

Published in Patient Educ Couns. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.